Loading patent…
AssigneeYeda Research and Development Co. Ltd.
InventorsIrun R Cohen, Varda Rotter, Roland Wolkowicz, Pedro Ruiz, Neta Erez-Alon, Johannes Herkel
Estimating the term…
The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.
A synthetic peptide capable of eliciting antibodies to p53, which peptide is 7 to 30 amino acids in length of a variable region of an anti-p53 mAb and contains a sequence of a CDR of the heavy chain or light chain of the anti-p53 mAb, and salts thereof, wherein the sequence of the CDR is selected from the polypeptide sequences of mAb 240, mAb 246 and mAb 421.
Dependencies are inferred from the claim text.